For instance, in data derived from the Rembrandt database, patients with gliomas (WHO grades II–IV) exhibiting high expression of TDO2 and AhR had considerably lower survival rates compared to those with intermediate or low expression11. This evidence concerns the gene AHR and central nervous system cancer.